Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19)
Katja Radon, Elmar Saathoff, Michael Pritsch, Jessica Michelle Guggenbühl Noller, Inge Kroidl, Laura Olbrich, Verena Thiel, Maximilian N. Diefenbach, Friedrich Riess, Felix Forster, Fabian J. Theis, Andreas Wieser, Michael Höelscher, Abhishek Bakuli, Judith Eckstein, Günter Froeschl, Otto Geisenberger, Christof Geldmacher, Arlett Heiber, Larissa Hoffmann, Kristina Huber, Dafni Metaxa, Michel Pletschette, Camilla Rothe, Mirjam Schunk, Claudia Wallrauch, Thorbjörn Zimmer, Stephan Prückner, Christiane Fuchs, Jan Hasenauer, Noemi Castelletti, Eleftheria Zeggini, Michael Laxy, Reiner Leidl, Lars Schwettmann
Abstract
BACKGROUND: Due to the SARS-CoV-2 pandemic, public health interventions have been introduced globally in order to prevent the spread of the virus and avoid the overload of health care systems, especially for the most severely affected patients. Scientific studies to date have focused primarily on describing the clinical course of patients, identifying treatment options and developing vaccines. In Germany, as in many other regions, current tests for SARS-CoV2 are not conducted on a representative basis and in a longitudinal design. Furthermore, knowledge about the immune status of the population is lacking. Nonetheless, these data are needed to understand the dynamics of the pandemic and hence to appropriately design and evaluate interventions. For this purpose, we recently started a prospective population-based cohort in Munich, Germany, with the aim to develop a better understanding of the state and dynamics of the pandemic. METHODS: In 100 out of 755 randomly selected constituencies, 3000 Munich households are identified via random route and offered enrollment into the study. All household members are asked to complete a baseline questionnaire and subjects ≥14 years of age are asked to provide a venous blood sample of ≤3 ml for the determination of SARS-CoV-2 IgG/IgA status. The residual plasma and the blood pellet are preserved for later genetic and molecular biological investigations. For twelve months, each household member is asked to keep a diary of daily symptoms, whereabouts and contacts via WebApp. If symptoms suggestive for COVID-19 are reported, family members, including children < 14 years, are offered a pharyngeal swab taken at the Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, for molecular testing for SARS-CoV-2. In case of severe symptoms, participants will be transferred to a Munich hospital. For one year, the study teams re-visits the households for blood sampling every six weeks. DISCUSSION: With the planned study we will establish a reliable epidemiological tool to improve the understanding of the spread of SARS-CoV-2 and to better assess the effectiveness of public health measures as well as their socio-economic effects. This will support policy makers in managing the epidemic based on scientific evidence.